adavosertib + topotecan + cisplatin

This drug is a **combination regimen of adavosertib, topotecan, and cisplatin** under investigation for cancer therapy. - **Adavosertib** is a small molecule inhibitor of WEE1, a protein kinase involved in cell cycle regulation. By inhibiting WEE1, adavosertib forces cells with DNA damage (such as cancer cells) to enter mitosis prematurely, leading to cell death[2][8]. - **Topotecan** is a **topoisomerase I inhibitor**, interfering with DNA replication and causing DNA damage and apoptosis in tumor cells[7]. - **Cisplatin** is a **platinum-based chemotherapeutic** that creates DNA crosslinks and triggers apoptosis in rapidly dividing cells[7]. This triple combination is being studied primarily for **advanced cervical cancer** and other solid tumors in phase I/II clinical trials[3]. The main developer for clinical trials is **Merck Sharp & Dohme**; adavosertib itself was developed by **AstraZeneca** (AZD1775), and the chemotherapy agents topotecan and cisplatin are standard drugs produced by various manufacturers. The addition of adavosertib is designed to sensitize cancer cells to DNA-damaging agents (topotecan and cisplatin), potentially improving efficacy.

Other names

adavosertib + topotecan + cisplatin